Определение наиболее информативных прогностических параметров для оценки статуса рецептора эпидермального фактора роста Her2/neu в основном опухолевом узле у больных раком молочной железы при использовании таргетного радионуклидного препарата «99mTc-ADAPT6»

The aim of the study was to identify the most informative prognostic parameters that allow assessing the status of the epidermal growth factor receptor Her2/neu in the primary tumor in breast cancer patients using the radiopharmaceutical «99mTc-ADAPT6». Material and methods. The study included 15 patients with breast cancer (T1-4N0-2M0) before the system therapy. Eight patients were found to overexpress Her2/neu in the primary breast tumor, in 7 cases the expression of the marker was not diagnosed. Morphological and immunohistochemical studies were performed in all cases. All patients are undergoing a radionuclide study using the radiopharmaceutical «99mTc-ADAPT6» at a dosage of protein 500 μg. Results. Patients with Her2-positive breast tumors showed a significantly higher accumulation of «99mTc-ADAPT6» in primary tumor (p<0.05, Mann-Whitney U test), as well as high tumor/background, tumor/latissimus dorsi muscle and tumor/liver as compared with patients with negative status of Her2/neu (p<0.005, Mann-Whitney U test). Based on the analysis performed using the logistic regression method, there was a mathematical model for predicting the Her2/neu status in primary tumor of breast cancer patients (specificity and sensitivity 100%; p=0.0002) Conclusion. The results of the study make it possible to consider the radiopharmaceutical «99mTc-ADAPT6» as an additional promising agent for determining the Her2/neu status in breast cancer patients. Key words: breast cancer, radionuclide diagnostics, alternative scaffold proteins, ADAPT6, Her2 / neu